Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- Domestic Sales of Ethical Drugs Rose 0.3% to 9,560.1 Billion Yen in FY2012: IMS Japan
May 22, 2013
- GSK Shares Clinical Trial Data with Researchers before Statistical Analysis
May 22, 2013
- Major Dispensing Pharmacy Chain Operators Expect Record High Sales and Profits in FY2013
May 21, 2013
- Five Major Dispensing Pharmacy Chain Operators’ Profits Down Due to NHI Price Revision
May 21, 2013
- Allegra AGs Pitched as Affordable Original Drugs with Production by Sanofi
May 21, 2013
- ALS Treatment Ozanezumab Designated as Orphan Drug: GSK
May 21, 2013
- AZ, BMKK Launch Once-Weekly GLP-1 Receptor Agonist Bydureon
May 20, 2013
- Takeda Slips to 3rd Place in 25 Major Pharmas’ Operating Profit Ranking
May 20, 2013
- Takeda’s Novel Diabetes Treatment GPR40 Shows Efficacy in Japanese Patients in PIII Trial
May 20, 2013
- New Rules on Settai Resulted in Fewer Serious Violations of Fair Competition Code in FY2012: Industry FTC
May 20, 2013
- 3 Major Generic-Only Makers Offer Mixed Views on Govt Promotion Measures
May 17, 2013
- FY2012 Sales Up 18% for Both Generic-Only Makers, Research-Driven Pharmas’ Generic Units; Govt Incentive Measures Biggest Contributor
May 17, 2013
- Toyama Chemical to License Novel Macrolide Agent from Cempra
May 17, 2013
- Yakult to File Elplat for New Indications of Pancreas and Gastric Cancer
May 17, 2013
- Astellas to File NDA for Enzalutamide in Japan in 1st Half of FY2013
May 17, 2013
- FY2012 Japan Pharma Market: Sales of Major Long-Listed Drugs Tumble 30-40%
May 16, 2013
- Astellas to Reorganize Research Functions, Shut Down US Subsidiaries
May 16, 2013
- Pres. Sagara Says Profit Increase Still Ways Away, Company to Invest to Enhance Pipeline: Ono
May 16, 2013
- PII Study of Terbinafine Patch for Tinea Unguium in US Shows No Significant Difference Against Placebo in Primary Endpoint: Hisamitsu
May 16, 2013
- Investigation on Ranbaxy Quality Issue Ends, Risks Eliminated: Daiichi Sankyo Pres.
May 15, 2013
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…